First-Trimester Screening of Open Neural Tube Defects Using Biometrics and Maternal Serum Markers

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorUniversity Hospital, Strasbourg, France

About this trial

Open neural tube defects are congenital malformations associated with significant morbidity. Early detection during the first trimester remains a key challenge.

This retrospective monocentric study aims to evaluate the diagnostic performance of fetal biometrics (biparietal diameter and abdominal transverse diameter ratios) and maternal serum markers (beta-hCG and PAPP-A) for early screening of open neural tube defects. The study will assess the predictive value of these parameters individually and in combination to define optimal screening thresholds applicable in routine clinical practice

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult pregnant woman (≥18 years)

First-trimester ultrasound performed at Strasbourg University Hospitals between 01/01/2011 and 31/12/2023

No written opposition to reuse of medical data for research purposes

Disqualifiers

Written opposition to reuse of medical data for research purposes

Multiple pregnancy

Presence of fetal growth abnormality, morphological or genetic anomaly during pregnancy

Crown-rump length <45 mm or >84 mm at screening ultrasound

Trial population

Pregnant women undergoing routine first-trimester ultrasound screening at Strasbourg University Hospitals, including both normal pregnancies and those complicated by open neural tube defects.

Trial design

Design model

Case-only

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Diagnostic performance of biometric ratios and serum markers

Determination of optimal thresholds for BPD/TAD and BPD/PA ratios and maternal serum markers (beta-hCG and PAPP-A) for screening of open neural tube defects, by comparing their diagnostic performance alone and in combination using ROC analysis.

Time frame
At first-trimester screening (retrospective data from 2011 to 2023)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.